Abstract

The microbiome, comprising trillions of microorganisms residing in and on the human body, has emerged as a pivotal player in human health, particularly in the context of agribusiness practices, genetic factors, and the rising obesity epidemic. This research embarks on an ethical exploration of the intricate interplay between these three domains. Agribusiness, with its emphasis on industrialized food production and widespread use of antibiotics and pesticides, has significantly impacted the diversity and composition of the human microbiome. Genetic predispositions further influence how individuals interact with their microbiomes, shaping susceptibility to conditions like obesity.

The obesity epidemic, a global health crisis, has been linked to alterations in the gut microbiota composition, which in turn can be influenced by diet, antibiotic use, and host genetics. This study aims to dissect the ethical implications of these interactions, exploring questions around informed consent in agribusiness practices, genetic privacy, and equitable access to microbiome-targeted therapies. It also delves into the role of public policy and regulation in mitigating the negative impacts of agribusiness on microbiome health. By integrating insights from ethics, microbiology, genetics, and public health, this research seeks to foster a more nuanced understanding of the microbiome’s role in health and disease, while advocating for responsible practices in agribusiness and personalized medicine.